10-K: Kenvue Reports Mixed FY25 Results Amid Kimberly-Clark Merger

Kenvue Inc. reported a 2.1% decline in net sales for fiscal year 2025, alongside a 42.7% increase in net income driven by lower impairment charges, as it progresses towards a merger with Kimberly-Clark Corporation.

Summary

• Net sales for fiscal year 2025 decreased by $331 million, or 2.1%, to $15.124 billion compared to $15.455 billion in fiscal year 2024.
• Organic sales decreased by 2.2%, driven by a 2.3% volume-related decrease, partially offset by 0.1% favorable value realization (price, including mix).
• Net income increased by $440 million, or 42.7%, to $1.470 billion in fiscal year 2025, up from $1.030 billion in fiscal year 2024, primarily due to significantly lower impairment charges.
• Operating income increased by $573 million, or 31.1%, to $2.414 billion in fiscal year 2025, compared to $1.841 billion in fiscal year 2024.
• Gross profit margin expanded by 10 basis points to 58.1% in fiscal year 2025.
• Selling, general, and administrative expenses decreased by $241 million, or 3.8%, to $6.088 billion, representing 40.3% of net sales, a 70 basis point decrease.
• Restructuring expenses increased by $105 million, or 56.8%, to $290 million in fiscal year 2025, primarily due to higher information technology and project-related costs under the 'Our Vue Forward' initiative.
• Impairment charges significantly decreased to $23 million in fiscal year 2025 (related to the ORSL trade name) from $578 million in fiscal year 2024 (primarily Dr.Ci:Labo assets and former HQ).
• Net cash flows from operating activities increased by $428 million, or 24.2%, to $2.197 billion in fiscal year 2025.
• The company is progressing with its proposed merger with Kimberly-Clark Corporation, with shareholders of both companies approving the merger agreement and the issuance of K-C common stock on January 29, 2026.
• Kenvue shareholders are expected to own approximately 46% of the combined company on a fully diluted basis upon completion of the merger.
• The 'Our Vue Forward' restructuring initiative is substantially completed, having realized annualized pre-tax gross cost savings in excess of $350 million by the end of fiscal year 2025.
• A new restructuring initiative was approved on February 17, 2026, expected to incur approximately $250 million in pre-tax charges in fiscal year 2026.
• The company completed the sale of its former corporate headquarters in Skillman, New Jersey, recognizing a $17 million gain in fiscal year 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative report. While net income increased, this was largely due to lower impairment charges. Underlying sales and organic growth declined across all segments, and the stock has significantly underperformed its peers and the broader market. The pending merger introduces uncertainty, and ongoing legal challenges remain a concern.

Positives

• Net income increased by 42.7% to $1.470 billion in fiscal year 2025, largely due to lower impairment charges.
• Operating income increased by 31.1% to $2.414 billion in fiscal year 2025.
• Gross profit margin expanded by 10 basis points to 58.1% in fiscal year 2025, driven by supply chain optimization benefits.
• Selling, general, and administrative expenses decreased by 3.8%, and as a percentage of net sales, decreased by 70 basis points, reflecting savings from 'Our Vue Forward' and lower separation-related costs.
• Net cash flows from operating activities increased by 24.2% to $2.197 billion, indicating strong operational cash generation.
• The 'Our Vue Forward' restructuring initiative has substantially completed, yielding over $350 million in annualized pre-tax gross cost savings.
• Shareholders of both Kenvue and Kimberly-Clark have approved the proposed merger, advancing the transaction towards its expected close in the second half of 2026.
• The company maintains investment-grade credit ratings and has adequate liquidity with $1.1 billion in cash and cash equivalents, a $4.0 billion revolving credit facility, and a $4.0 billion commercial paper program.

Negatives

• Net sales decreased by 2.1% to $15.124 billion in fiscal year 2025.
• Organic sales decreased by 2.2%, primarily due to volume declines across segments.
• Volume-related decreases were impacted by trade inventory reductions by retailers in the United States, changes in shipment timing in China, and lower seasonal incidences affecting Allergy Care, pediatric Pain Care, and Cough and Cold products.
• The Skin Health and Beauty segment experienced a 3.0% decrease in net sales and a significant 21.4% decrease in adjusted operating income, attributed to distribution losses, e-commerce underperformance, competitive pressures, and a softer sun season in the United States.
• Restructuring expenses increased by 56.8% to $290 million in fiscal year 2025.
• The company's common stock underperformed both the S&P 500 Stock Index and the S&P 500 Consumer Staples Stock Index from May 4, 2023, through December 28, 2025.
• The proposed merger with Kimberly-Clark fixes the exchange ratio, meaning the market value of the stock consideration Kenvue shareholders receive will fluctuate with K-C's stock price.

Risks

• Failure to realize the projected benefits and cost savings from the proposed merger with Kimberly-Clark, or delays in its consummation, could adversely affect the value of K-C common stock and Kenvue's business.
• Uncertainties associated with the proposed merger may lead to a loss of management and other key employees.
• Kenvue shareholders will have a significantly reduced ownership and voting interest in the combined company post-merger.
• Ongoing litigation against Kenvue or Kimberly-Clark related to the merger could delay or prevent its completion.
• Regulatory approvals for the merger, particularly foreign regulatory approvals, may be delayed or impose conditions that diminish benefits.
• Concerns about the reliability, safety, or efficacy of products or their ingredients (e.g., acetaminophen, talc, phenylephrine, benzoyl peroxide) could result in litigation, regulatory action, reputational damage, product recalls, reformulations, or withdrawals.
• Legal proceedings related to talc or talc-containing products sold outside the United States and Canada remain Kenvue's responsibility and could adversely affect the company.
• Intense competition from multinational corporations, regional companies, private-label brands, and generic products across all business segments and geographic markets.
• Inability to anticipate, understand, and respond appropriately to market trends and rapidly changing consumer and customer preferences in a timely manner.
• Damage to Kenvue's or its brands' reputation due to negative publicity, whether valid or not, or issues with third-party partners.
• Challenges in implementing Kenvue's digital strategy, including e-commerce and connected health offerings, could expose the company to new risks.
• Uncertainty in the development, deployment, use, and regulation of artificial intelligence could adversely affect Kenvue's business.
• Reliance on third parties for manufacturing, supply chains, and distribution inherently involves less control and exposes Kenvue to additional risks.
• Disruptions to manufacturing or supplier operations (e.g., regulatory action, quality issues, labor disputes, raw material shortages, geopolitical events) could lead to product shortages and declining sales.
• Volatility in the cost or availability of raw materials and other inputs (e.g., resins, silicon, energy, labor, transportation) due to inflation, military conflicts, or tariffs could adversely affect profitability.
• Information security incidents, including cybersecurity breaches, or failure of technology systems could result in reputational damage, operational disruption, and significant costs.
• Inability to attract and retain talented, highly skilled employees and implement effective succession plans for senior management.
• Labor disputes, strikes, work stoppages, or increases in minimum wages could adversely affect operations and costs.
• Climate change, extreme weather, or new environmental regulations could disrupt supply chains and increase operational costs.
• Increasing scrutiny and evolving expectations regarding sustainability matters could lead to reputational damage or increased compliance costs.
• Insurance coverage may be insufficient to cover potential losses, particularly for product liability and cybersecurity.
• Significant product returns or refunds could adversely affect financial results.
• Changes in tax laws or exposures to additional tax liabilities could negatively impact the effective tax rate.
• Foreign currency fluctuations and other risks associated with conducting business globally, including political instability and trade tensions.
• Impairment of goodwill and other intangible assets could result in a reduction in net income.
• Changes to credit ratings or disruptions in credit markets could reduce access to credit or overall liquidity.
• Kenvue's dependence on subsidiaries for cash flow to meet its obligations, with potential legal, tax, and contractual restrictions on dividend payments from subsidiaries.
• The company's continued use of legacy J&J branding could be adversely affected by events impacting J&J's reputation.
• Potential indemnification obligations to J&J for certain liabilities, including OTC Zantac claims, could result in substantial liabilities for Kenvue.

Future Outlook

Kenvue expects the proposed merger with Kimberly-Clark Corporation to close in the second half of 2026, subject to customary closing conditions including foreign regulatory approvals. The company anticipates continued transformation with a new restructuring initiative in fiscal year 2026, aiming to optimize its operating model and drive efficiencies. Kenvue will continue to monitor macroeconomic developments, including inflation and trade policies, and their potential impact on business. The company expects to continue paying quarterly cash dividends, though this is subject to Board discretion.

Management Comments

• Management believes reporting period-over-period changes in Organic sales provides investors with supplemental information that is useful in assessing our results of operations by excluding the impact of certain items that we believe do not directly reflect our underlying operations.
• Management believes that our cash balances and funds provided by operating activities, along with borrowing capacity and access to capital markets, taken as a whole, provide adequate liquidity to meet all of our current and long-term obligations when due, including third-party debt, adequate liquidity to fund capital expenditures, and flexibility to meet investment opportunities that may arise.
• Management believes these cost allocations (from J&J prior to Kenvue IPO) are a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the periods presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company.

Industry Context

StockSavvy.ai notes that Kenvue operates in a highly competitive and dynamic consumer health and personal care sector, facing challenges from established CPG companies, niche brands, and private-label products. The reported decline in organic sales, particularly in Skin Health and Beauty, suggests Kenvue is navigating a challenging retail landscape marked by increased trade concentration, rapid e-commerce growth, and evolving consumer preferences towards preventative care and science-backed solutions. The pending merger with Kimberly-Clark represents a significant industry consolidation, aiming to leverage scale and potentially create synergies in a competitive market. The ongoing legal scrutiny of ingredients like acetaminophen and phenylephrine reflects broader regulatory and consumer safety trends impacting the OTC drug industry.

Comparison to Industry Standards

• Kenvue's stock performance from May 4, 2023, through December 28, 2025, yielded a return of -$29.58 on an initial $100 investment, significantly underperforming the S&P 500 Stock Index (+$77.13) and the S&P 500 Consumer Staples Stock Index (+$17.05) over the same period.
• The decline in organic sales across all segments, particularly the 2.7% decrease in Skin Health and Beauty, indicates challenges in market share and consumer demand compared to broader industry growth trends, which often see consumer staples maintaining stability or modest growth.
• The fixed exchange ratio in the Kimberly-Clark merger means Kenvue shareholders' future value is tied to Kimberly-Clark's performance, a direct competitor in some Essential Health categories (e.g., Procter & Gamble, Colgate-Palmolive, Haleon, Church & Dwight also compete in these segments).

Management Changes

Corporate Governance

Legal Proceedings

• Multiple product liability claims and lawsuits alleging in utero exposure to acetaminophen (Tylenol) is associated with autism spectrum disorder and/or attention-deficit/hyperactivity disorder in children. Federal cases were dismissed in 2024 and are on appeal. The State of Texas filed a petition in October 2025, with claims against Kenvue and J&J dismissed in November 2025, also on appeal. The FDA initiated a label change process for acetaminophen in September 2025.
• Claims for personal injury alleging talc causes cancer, primarily from Johnson's Baby Powder. J&J indemnifies Kenvue for Talc-Related Liabilities in the United States and Canada. Kenvue remains responsible for claims outside these regions, including pending claims in the United Kingdom and a recently announced proceeding in Australia.
• Putative class actions and shareholder derivative complaints filed following the September 2023 NDAC conclusion that orally administered phenylephrine (PE) is not effective as a nasal decongestant. The FDA issued a proposed order to remove PE from the OTC monograph in November 2024.
• Putative class actions filed in March 2024 against Kenvue and other manufacturers of benzoyl peroxide (BPO)-containing acne products, alleging degradation into benzene.

Related Party Transactions

• Kenvue continues to have material agreements with Johnson & Johnson (J&J) following the Separation, including the Separation Agreement, Tax Matters Agreement, Transition Services Agreement, and Transition Manufacturing Agreement.
• The Transition Services Agreement program with J&J was completed in April 2025, with Kenvue finalizing the exit of over 2,300 transition services.
• J&J provides certain manufacturing services to Kenvue under the Transition Manufacturing Agreement for a transitional period.
• Kenvue has indemnification obligations to J&J for certain liabilities relating to Kenvue's business activities, including legal claims related to OTC Zantac products sold by third parties in the United States.
• J&J has agreed to indemnify Kenvue for certain liabilities, including Talc-Related Liabilities for products sold in the United States and Canada.

Stakeholder Impact

• Shareholders: The proposed merger with Kimberly-Clark will result in Kenvue shareholders owning approximately 46% of the combined company, diluting their ownership and voting interest in Kenvue as a standalone entity. The fixed exchange ratio ties their future value to K-C's stock performance. The stock has underperformed market indices.
• Employees: Restructuring initiatives ('Our Vue Forward' and a new 2026 initiative) involve global workforce reductions and changes in management structure, potentially impacting employee morale and retention. The merger also creates uncertainty regarding roles within the combined company.
• Customers: Retailer inventory management and competitive pressures have led to trade inventory reductions and market share losses, impacting sales volumes. The merger could affect existing business relationships.
• Consumers: Concerns about product safety and efficacy (e.g., acetaminophen, talc, phenylephrine, BPO) could lead to reduced consumer confidence, declining sales, and product recalls. The company's focus on science-backed innovation and digital strategy aims to meet evolving consumer preferences.
• Suppliers: Reliance on third-party manufacturers and suppliers, particularly single-source suppliers for key components, exposes the company to risks of disruption and increased costs. The completion of the Transition Services Agreement means Kenvue must replace services previously provided by J&J.
• Creditors: Kenvue maintains substantial debt obligations, but is in compliance with all debt covenants. The company's ability to generate cash flow from operations is crucial for servicing debt and maintaining liquidity.

Next Steps

• Complete the proposed merger with Kimberly-Clark Corporation, expected in the second half of 2026.
• Implement a new restructuring initiative approved on February 17, 2026, incurring approximately $250 million in pre-tax charges in fiscal year 2026.
• Continue the relocation to the new research and development building in Summit, New Jersey, with completion expected through 2026.
• Monitor and respond to ongoing legal proceedings related to acetaminophen, talc, phenylephrine, and benzoyl peroxide.
• Continue to monitor the performance of the Skin Health and Beauty business for potential future goodwill impairment.
• Redeem the 5.35% Senior Notes due 2026 on February 23, 2026.
• Continue to evaluate the Model Global Anti-Base Erosion Rules for Pillar Two and related legislation for potential impact on future tax provisions.

Key Dates

Recommendation

The recommendation is 'hold' for existing shareholders due to the impending merger with Kimberly-Clark. The fixed exchange ratio means Kenvue's future value is largely tied to K-C's stock performance and the successful completion of the transaction. While Kenvue's underlying sales performance is weak, the significant increase in net income (driven by lower impairment charges) and strong operating cash flow provide some stability. For new investors, the current filing does not present a compelling standalone investment case given the sales decline and the uncertainty of the combined entity's performance post-merger, making a 'hold' appropriate for those already invested and awaiting the merger's outcome.

Keywords

Consumer Health, Kenvue, Kimberly-Clark Merger, SEC Filing, 10-K, Financial Results, Net Sales, Net Income, Organic Sales, Consumer Packaged Goods, Self Care, Skin Health and Beauty, Essential Health, Restructuring, Supply Chain, Product Liability, Acetaminophen, Talc, Phenylephrine, Cybersecurity, Corporate Governance, Dividend, Stock Repurchase, J&J Separation